New York State Common Retirement Fund Has $3.66 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

New York State Common Retirement Fund reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.6% in the 4th quarter, HoldingsChannel reports. The firm owned 23,382 shares of the company’s stock after selling 2,481 shares during the period. New York State Common Retirement Fund’s holdings in Krystal Biotech were worth $3,663,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of KRYS. Segall Bryant & Hamill LLC lifted its stake in Krystal Biotech by 352.4% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock valued at $28,605,000 after purchasing an additional 122,407 shares during the last quarter. State Street Corp lifted its position in Krystal Biotech by 9.0% during the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after acquiring an additional 119,936 shares during the last quarter. Franklin Resources Inc. lifted its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock worth $43,774,000 after acquiring an additional 62,178 shares during the last quarter. Braidwell LP lifted its position in Krystal Biotech by 57.4% during the third quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after acquiring an additional 61,512 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in Krystal Biotech during the third quarter worth approximately $5,872,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday. Finally, Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $215.83.

Insider Activity at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Trading Up 3.4 %

NASDAQ KRYS opened at $179.25 on Friday. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a 50 day moving average of $159.41 and a 200-day moving average of $175.26. The company has a market cap of $5.16 billion, a price-to-earnings ratio of 59.95 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the business earned $0.30 earnings per share. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).